HRMY
NASDAQ
$33.50
Harmony Biosciences Holdings Inc (HRMY)
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and markets therapies for patients with rare neurological disorders. The company is headquartered in Plymouth Meeting, Pennsylvania.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $44.91 (+34.06%)
Market Cap
$2.02B
Revenue 5Y CAGR
+37.73%
FCF 5Y CAGR
+56.64%
Forward P/E
10.71
Price Chart
Valuation
Market Cap$2.02B
P/E13.82
Forward P/E10.71
P/S2.25
P/B2.21
Profitability
Total Revenue (TTM)$899M
Gross Profit (TTM)$688M
EBITDA$211M
Profit Margin15.1%
Operating Margin17.3%
EPS$2.53
Financial Health
Debt-to-Equity17.4%
Free Cash Flow Yield16.92%
Growth & Risk
Revenue 5Y CAGR+37.73%
FCF 5Y CAGR+56.64%
Beta (5Y)0.62
Sharpe Ratio-0.07